We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Lecanemab, the antiamyloid antibody being jointly developed by Eisai and Biogen, grabbed the clinical trial world with a fresh look at extension data and news of its inclusion in an important treatment trial for genetically driven Alzheimer’s disease.